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ASSESSMENT OF THE DISCRIMINATIVE STIMULUS EFFECTS OF
(±)-3,4-METHYLENEDIOXYMETHAMPHETAMINE
(MDMA, "ECSTASY”) AND (+)-LYSERGIC ACID
DIETHYLAMIDE (LSD) IN A THREE-LEVER
DRUG DISCRIMINATION PROCEDURE
Amy K. Goodwin, Ph.D.
Western Michigan University, 2002
(±)3,4-Methylenedioxymethamphetamine (MDMA) is a common drug of
abuse known as "ecstasy." Currently, MDMA is classified into the traditional drug
classes as both a "stimulant" and a "hallucinogen" because it is reported to share both
subjective and physiological properties of both classes. MDMA is thought to produce
its psychoactive effects by acting as both a serotonin and a dopamine agonist.
However, the relative importance of the serotonin and dopamine neurotransmitter
systems in mediating the stimulus properties of MDMA remains unclear.
The drug discrimination assay is used to classify drugs as "similar" or
"dissimilar," as well as to examine underlying neurochemical changes associated with
the stimulus properties of psychoactive compounds. Two-lever drug discriminations
comparing the stimulus properties of MDMA to other psychostimulants and
hallucinogens have produced conflicting reports.

However, Goodwin and Baker

(2000) established that rats could be successfully trained to discriminate damphetamine, a dopamine agonist, and MDMA from saline in a three-lever drug
discrimination procedure. The present study sought to train 12 rats to discriminate
(+)-lysergic acid diethylamide (LSD), a serotonin agonist, and MDMA from saline in
a similar three-lever procedure.
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All subjects acquired the discrimination, though it appears the stimulus effects
of LSD and MDMA are difficult to distinguish. This is evidenced by the difficulties
establishing and demonstrating maintenance of the discrimination in the beginning
stages of the study. Overall, subjects required an average of 153 training sessions in
order to demonstrate adequate stimulus control.
d-Amphetamine produced only partial substitution for MDMA while the
serotonin releaser, fenfluramine, did completely substitute for MDMA.

Low doses

of both d-amphetamine and fenfluramine given in combination substituted for
MDMA at only one of the combinations. Moreover, the serotonin antagonist MDL100907 only partially blocked the MDMA cue while the dopamine antagonist
haloperidol did not produce any decrease in MDMA responding. Conversely, MDL100907 did completely block the LSD cue.
Taken together, these results support the notion that the stimulus effects of
MDMA are clearly different from those of other psychostimulants and hallucinogens,
and should therefore be classified into a distinct drug class. Indeed, Nichols (1986)
has proposed that MDMA and similar amphetamine analogs belong in a separate drug
class, for which he has coined the term "entactogens." It also is evident that whether
animals are trained to discriminate MDMA from d-amphetamine or from LSD,
serotonin release is a salient feature of MDMA discrimination.
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CHAPTER I

INTRODUCTION

(±)-3,4-methylenedioxymethamphetamine (MDMA/Ecstasy)

The History of MDMA
(±)-3,4-methylenedioxymethamphetamine (MDMA) is often described as a
“designer drug”, referring to compounds created by untrained chemists to be
structurally similar to illegal psychoactive substances. These drugs were popular in
the late 1970’s and early 1980’s because they often produced similar effects to illegal
substances but were not illegal themselves. Hence, they were “designed” after
existing illegal compounds to produce similar effects. In 1986 the Controlled
Substances Analog Act (CSAA) was created to make this practice illegal (Grilly,
1998). However, though sometimes mistakenly reported otherwise, MDMA was not
“designed” after its parent compound, d-amphetamine. Although it is structurally
similar to d-amphetamine, MDMA was not initially created by lay chemists for
recreational use. It is also often erroneously reported that MDMA was manufactured
as a potential appetite suppressant for German soldiers during World War II (Holland,
2001; Pentney, 2001). In fact, a chemically related compound,
methylenedioxyamphetamine (MDA), was synthesized by Smith Kline French in
1958 and tested as an appetite suppressant (Holland, 2001; Stafford, 1992). As a

1
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recreational drug, MDA became popular in the mid-1960s, before MDMA was ever
used recreationally (Beck & Rosenbaum, 1994; Stafford, 1992).
MDMA was originally produced by Merck, a German pharmaceutical
company, in the early 1900’s when their scientists were attempting to develop a
vasoconstrictive drug (i.e., hydrastinin)(Holland, 2001). MDMA was one compound
produced in the synthesis of hydrastinin. Indeed, when Merck filed for a patent for
hydrastinine in 1912, MDMA was listed as one of the intermediate chemicals (Beck,
1997; Holland, 2001; Pentney, 2001). Thus, MDMA was included when Merck was
granted the patent in 1914.
In 1953 the United States Army funded classified research, declassified in
1969, investigating the toxicity of psychoactive compounds (e.g., mescaline, MDA,
MDMA) and animals (e.g., rats, mice, dogs, monkeys) (Hardman, Haavik, & Seevers,
1973; Holland, 2001; Pentney, 2001; Stafford, 1992). The research was conducted at
the University of Michigan as part of a chemical warfare research project by the
United States Army. As a result of these studies, MDMA was described as less toxic
than MDA and no neurotoxicity was reported (Hardman et al., 1973; Pentney, 2001).
It is reported that Dr. Sasha Shulgin obtained a sample of MDMA in the early
1970’s and introduced it to colleagues who were therapists, as a potential therapeutic
tool (Holland, 2001). As a result, in 1976 a fair number of therapists began
prescribing MDMA as an adjunct to psychotherapy (Greer & Tolbert, 1986;
McDowell & Kleber, 1994), reportedly to enhance communication and “self
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examination”. One psychotherapist, Les Zeff, Ph.D., is reported to have administered
MDMA during hundreds of treatment sessions without publishing any accounts
(Pentney, 2001). It is during this time that MDMA was referred to as “Adam”. This
in combination with the decision to not publish any reports of the use of MDMA
during sessions was an attempt by Zeff to avoid alerting the media and the Drug
Enforcement Agency (DEA) to the clinical use of MDMA (Pentney, 2001). It wasn’t
until 1978 that the first report of the usefulness of MDMA in humans was published.
Shulgin and Nichols (1978) reported that the subjective effects of MDMA included
altered states of consciousness with emotional components such as empathy,
acceptance, and insight. Following this report, MDMA started to gain popularity as
an adjunct to psychotherapy, and as a recreational drug.
Recreational use of MDMA was on the rise in the early 1980’s and had gained
the common name of “ecstasy” (Eisner, 1989). A group of chemists known as the
“Boston Group” began to produce and sell MDMA and in 1981 one of these chemists
branched out into Texas and began manufacturing and selling MDMA with a group
of entrepreneurs (i.e., the “Texas Group”) under the name “Sassyfras” (Collin &
Godfrey, 1997; Eisner, 1989; Pentney, 2001). Sassafras is an organic oil that is a
precursor to the MDMA molecule (Collin & Godfrey, 1997; Eisner, 1989).
Purchases of MDMA were typically made through mail order. Indeed, this is the case
historically; most substances of abuse were sold legally though mail order before
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becoming illegal (Ray & Ksir, 1999). This includes amphetamine, cocaine, and even
heroin.

Legal History and Current Status of MDMA
Citing nationwide abuse and the potential health problems of MDMA, the
DEA began the process o f classifying MDMA as a Schedule I drug under the
Controlled Substances Act of 1970 in July of 1984 (Eisner, 1989; Ray & Ksir, 1999).
As part of this process, the DEA granted an appeal from a group of psychotherapists,
psychiatrists, and researchers who had requested hearings on the subject of
therapeutic use of MDMA. Hearings were held in Los Angeles, Kansas City, and
Washington, D.C. In the meantime, the DEA invoked the 1984 Comprehensive
Crime and Control Act, which allows emergency scheduling of compounds during the
hearing process if the risk to the public from the substance is perceived to be high
(Beck & Rosenbaum, 1994; Holland, 2001; McDowell & Kleber, 1994). In May of
1986, Francis Young, the judge overseeing the hearings, recommended to the DEA
that MDMA be listed as a Schedule III drug in order to allow research and clinical
applications to continue (Beck & Rosenbaum, 1994; Holland, 2001). The DEA
however, ignored this recommendation and MDMA became a Schedule I compound.
Following several appeals and temporary un-scheduling of MDMA, it was classified
permanently as a Schedule I compound in March of 1988 and remains there today.
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Once made illegal, the production and consumption of MDMA did not stop
and continues to be manufactured and used recreationally. In the late 1980’s the
phrase “club drugs” became popular as a way to describe psychoactive substances
teenagers and young adults were administering at all night dance parties, known as
“rave” parties. These dance parties, which typically draw five to thirty thousand
attendees, center around loud music, flashing lights, and dancing for eight to twelve
hours at a time (Reynolds, 1998). Originally, rave dance parties become popular in
the United Kingdom in the late 1980’s but have since spread throughout the world
(Collin & Godfrey, 1997; McDowell & Kleber, 1994). Several compounds have been
included in a group of drugs known as “club drugs” because they are commonplace at
the raves. These substances include MDMA (ecstasy), MDA (Eve), psilocybin
(mushrooms), ketamine (special K), and gamma-hydroxybutyrate (GHB). Even
drugs such as lysergic acid diethylamide (LSD) and alcohol have been described as
“club drugs” because they are often used at these all-night parties. Although there
was some general public concern as the phenomenon of all night drug festivities
became more popular, it was more or less viewed as an isolated issue that only
concerned those participating in the “rave” culture. Unfortunately, this was not to
remain the case.
Throughout the 1990’s the incidence of MDMA use has consistently increased
throughout the world. It is no longer confined to the “club” environment but has
become popular on university campuses and continues to gain popularity, particularly
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with adolescents and young adults. For example, the National Institute on Drug
Abuse (NIDA) funds an annual study conducted at the University of Michigan
entitled the Monitoring the Future Study, which reports that 5.5% of 12th graders in
1999 and 8% of 12th graders in 2000 reported using MDMA within the prior year.
The 2000 National Household Survey on Drug Abuse reports that 6.5 million
Americans have reported trying MDMA; and the Community Epidemiology Work
Group reports that in 1990 there were a mere 8 mentions of MDMA in emergency
room visits but in 1999 there were 796 mentions of MDMA in emergency room visits
(NIDA Infofax, 2002). Moreover, NIDA reported that the percentage of college
students who reported having used MDMA in the past year almost increased three
fold from 1991 (0.9 percent) to 1997 (2.4 percent).

Physiological Effects of MDMA
The cardiovascular effects reported by users and measured in the laboratory in
humans typically involve increases in heart rate and blood pressure (de la Torre,
Farre, & Ortuno, 2000; Mas, Farre, & de la Torre, 1999; Vollenweider, Gamma,
Liechti, & Huber, 1998). There have been some isolated cases of significant
hypertension reported in healthy volunteers. For example, Mat el al. (1999)
administered two doses of MDMA (75 mg and 125 mg) to eight volunteers and
reported that four of them were hypertensive after both doses. However, it does not
appear that the scientific literature regarding human subjects as a whole supports the

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

7

notion of a linear relationship between the dose of MDMA and changes in blood
pressure and heart rate (Baggot & Jerome, 2001).
Animal studies have produced conflicting results regarding cardiovascular
changes. Gorder, Watkinson, O’Callaghan, & Miller (1991) reported that a dose of
20 mg/kg of MDMA in rats significantly elevated heart rate and that the increase was
still evident six hours after administration. Indeed, the treatment proved to be lethal
in three of the five subjects. O’Cain, Hletko, Ogden, & Varner (2000) reported that a
dose of 3.0 mg/kg of MDMA significantly decreased the heart rate of rats. A dose of
1.0 mg/kg also decreased heart rate, though not significantly, while doses of 0.01
mg/kg and 0.1 mg/kg resulted in non-significant increases in heart rate. Fitzgerald &
Reid (1994) reported that MDMA (1 and 10 pm) significantly increased the heart rate
of perfused, isolated, rat heart tissue in vitro.
Also observed in humans are thermoregulatory impairments, typically
involving increases in body temperature (Liechti & Vollenweider, 2000a; Mas et al.,
1999; Parrott, 2001). The environment in which the MDMA is taken can exacerbate
this effect, as “ravers” typically spend long periods of time dancing within confined
and crowded spaces and may consume other psychoactive substances. Indeed, a
number of deaths among MDMA users participating in “raves” have been reported
and attributed to hyperthermia (Cohen, 1998; Green, Cross, & Goodwin, 1995;
Parrott, 2001). However, these deaths were also associated with other medical
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problems, such as renal failure, cardiac arrest, liver failure, and cerebral hemorrhage
(Parrott, 2001).
Thermoregulatory impairment is also reported in non-humans. Meehan,
O’Shea, Elliot, Colado, & Green (20021) reported that a neurotoxic doses of MDMA
(12.5 mg/kg) resulted in hyperthermia as soon as 30 minutes after administration and
persisted for up to 3.5 hours in Sprague-Dawley rats. Six weeks later there was no
difference in resting body temperature between MDMA and saline injected subjects.
However, when subjects were exposed to a “thermoregulatory challenge” (i.e.,
placing the subjects in a room with a high ambient temperature, 30° ± 0.5° C) the
body temperature in the rats exposed to MDMA were observed to increase to higher
levels than the saline control rats. Moreover, the heightened body temperature
persisted much longer in the MDMA pretreated rats than in the saline pretreated rats.
Other investigators (Malpass, White, Irvine, Somogyi, & Bochner, 1999) have
reported that administration of non-lethal doses o f MDMA (2, 5, 10 mg/kg) did not
result in a significant difference in body temperature between MDMA and saline
treated subjects in the Sprague-Dawley strain. However, when a Dark Agouti strain
of rats was used as subjects, there was a dose-dependent increase in body
temperature, and the 10 mg/kg dose was lethal in the first two subjects exposed to this
dose, precluding additional testing at this dose with this strain. The Dark Agouti
strain of rats are deficient in an enzyme, cytochrome P-450 2D1 (CYP2D1), which is
a proposed contributor to MDMA toxicity (Malpass et al., 1999)
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Other physiological changes that are reported in humans are indicative of
sympathetic nervous system activation and include an increase in pupillary diameter
and ocular muscle tension (Cami, Farre, & Mas, 2000; Downing, 1986), lack of
appetite, jaw clenching, dry mouth, restlessness, perspiration, nausea, insomnia,
tremor, fainting, blurred vision, and headache (Cohen, 1995; Curran & Travill, 1997;
Davison & Parrott, 1997; Peroutka, Newman, & Harris, 1988; Schifano, 2000; Siegal,
1986; Solowij, Hall, & Nicole, 1992).

Neurochemical Changes Associated with MDMA Administration
There appear to be two major neurotransmitter systems involved in mediating
the pharmacological effects of MDMA: serotonin and dopamine. The effects of
MDMA on serotonin are typically described as both facilitating the presynaptic
release (Johnson, Hoffman, & Nichols, 1986; McKenna, Guan, & Shulgin, 1991;
Nichols, Lloyd, Hoffman, Nichols, & Yim, 1982; Schmidt, Levin, & Lovenberg,
1987) and blocking the reuptake (Gold & Koob, 1989). The serotonin transporter is
reported to be of primary importance in MDMA’s neurochemical effects (Malberg &
Bonson, 2001). By occupying these transporters, MDMA prevents endogenous
serotonin from binding and this results in MDMA being deposited into the
presynaptic cell. Once MDMA is in the presynaptic cell it facilitates the release of
serotonin. Evidence of the importance of the serotonin transporter in mediating the
effects has been illustrated by Bengal, Murphy, Andrews, Wichems, Feltner, Heils,
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Mossner, Westphal, & Lesch (1998). They used a transgenic serotonin transporter
knockout mouse to demonstrate that MDMA-induced locomotion does not occur in
the absence of serotonin transporters.
MDMA also facilitates the presynaptic release of dopamine (Johnson et al.,
1986; Yamamoto & Spanos, 1988) and blocks the reuptake of dopamine (Steele,
Nichols, & Yim, 1987) but to a lesser degree than that of serotonin. Additionally, the
increase in dopamine release appears to be dependent upon occupation of serotonin
transporters by MDMA (Nash & Brodkin, 1991). Gudelsky & Nash (1996) reported
that administration of a compound that increases serotonin synthesis before the
administration of MDMA will result in an increase in dopamine release when
compared to administration of MDMA alone. Moreover, administration of a
serotonin-2 antagonist prior to MDMA administration blocks the increase in
dopamine release (Schmidt, Taylor, Abbate, & Nieduzak, 1991). If dopamine is
involved in neurotoxic effects of MDMA, 5-HT 2 antagonists may prove useful in
preventing these effects from occurring.

Neurotoxic Effects of MDMA
The neurotoxic effects that have been consistently reported in humans and
non-humans include long-term decreases in serotonin, its metabolite 5-HIAA,
serotonin transporter density, and tryptophan hydroxylase, a rate-limiting enzyme in
5-HT synthesis. A variety of methods, including neuroanatomical, neurochemical,
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and functional measures have been used to examine the neurotoxic effects of MDMA
on serotonin neurons in a variety of species (Ricaurte, Yuan, & McCann, 2000).
Some of these techniques include immunocytochemical methods (Molliver, Berger,
Mamounas, Molliver, O'Heam, & Wilson, 1990; Ricaurte et al., 2000), silver
degeneration studies (Commins, Vosmer, Virus, Woolverton, Schuster, & Seiden,
1987), imaging techniques (Holland, 1999; McCann, Szabo, Scheffel, Mathews,
Dannals, Ravert, Musachio, Mertl, & Ricaurte, 1998; Scheffel, Szabo, Mathews,
Finley, Dannals, Ravert, Szabo, Yuan, & Ricaurte, 1998), and anterograde transport
analysis (Ricaurte et al., 2000).
Mayerhofer, Kovar, & Schmidt (20001) used High Performance Liquid
Chromatography (HPLC) to examine brain tissue of rats exposed to 20 mg/kg of
MDMA for ten consecutive days. They found reduced levels of serotonin in the
forebrain, at both two and four weeks post-MDMA administration.
Croft, Klugman, Baldeweg, & Gruzelier (2001) employed electrophysiology
to examine decreases in serotonin levels in humans. Using EEGs and EOGs, they
measured subjects auditory intensity dependence function, an electrophysio logical
index of serotonin function (Juckel, Molnar, Hegerl, Csepe, & Karmos, 1997). Croft
et. al (2001) reported that long-term MDMA users demonstrated serotonin
dysfunction when compared to cannabis users and drug-naive subjects.
Indirect evidence that serotonin transporters are involved in the neurotoxic
effects of MDMA is illustrated by evidence that selective serotonin reuptake
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inhibitors (SSRIs) prevent MDMA-induced serotonin depletion in rats (Schmidt,
1987; Virden & Baker, 1999). Additionally, at least three studies in humans have
reported that taking an SSRI prior to common doses of MDMA reduces the positive
and negative effects reported by users (Liechti & Vollenweider, 2000a;2000b; Stein
& Rink, 1999). However, McCann & Ricaurte (1993) reported that four subjects who
ingested the SSRI fluoxetine prior to taking MDMA stated that the subjective effects
of MDMA were still experienced. Additionally, McCann, Eligulashvili, & Ricaurte
(2000) reported that positron emission tomography (PET) studies document MDMAinduced neutoxocity in nonhuman primates, as well as humans with a history of
MDMA use through measurement of [1 IC]McN-56 52-labeled serotonin transporter
sites. McCann et. al (2000) also reported that the degree of decrease in serotonin
transporter sites in humans can be correlated with the amount of MDMA exposure.
Indeed, there is little doubt that MDMA is neurotoxic and produces deficits
that can be replicated across laboratories and species. What remains in question is
whether these deficits correlate with functional or behavioral disruptions. Reports
regarding human behavioral and cognitive correlates of MDMA neurotoxicity are
conflicting. In a review of cognitive and behavioral indices of MDMA neurotoxicity
in humans, Pattott (2000) reported that there are three common areas where MDMA
users display deficits: impaired working memory, impaired higher order processing,
and increased impulsivity. However, Parrott also reported that there were several
cognitive measures where MDMA neurotoxicity did not impair performance,
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including reaction time, vigilance, and verbal fluency. Indeed, Parrott reported that in
some instances MDMA users had greater verbal abilities and spatial recall (Turner,
Godolphin, & Parrott, 1999) when compared to non-users. McCann, Mertl,
Eligulashvili, & Ricaurte, (1999) correlated significant decreases in 5-HIAA in
cerebrospinal fluid (CSF) of MDMA users with cognitive performance in the same
subjects. They found that MDMA users had significant deficits in measures of
attention involving math tasks, complex attention and incidental learning, short-term
memory and verbal reasoning. However, the MDMA users were also reported to
perform the same as non-users on measures on several other cognitive tasks,
including time estimation, matching to sample, and delayed recall. McCann et al.,
(1999) state that the differences between the groups are small, though they maintain
they are significant.
Investigations of neurotoxicity and cognitive and behavioral deficits are
equally conflicting in the literature regarding non-human animals. Moreover, at least
one study reported that MDMA enhanced associative and non-associative learning in
rabbits (Romano & Harvey, 1994). Regardless, both long- and short-term
neurotoxicty have been documented in both humans and non-humans and should,
therefore, be considered when designing and executing MDMA studies.
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Subjective Effects o f MDMA
MDMA is a phenylthylamine, a structural analog of d-amphetamine and
reportedly possesses both hallucinogenic and stimulant properties (Callahan & Appel,
1988; Evans & Johanson, 1986; Schechter, 1986). It is difficult to obtain reliable and
valid information regarding the subjective effects of any psychoactive compound
because of the inherent procedural issues required to gather data. These methods
typically include self-report and anecdotal reports. Although there are inherent
problems with these methods, there does seem to be a profile of the subjective effects
that is common to MDMA, and distinguishable from other psychoactive compounds
(Bravo, 2001).
The first published report regarding the subjective effects o f MDMA came
from Shulgin and Nichols (1978). Following this report, others also published
accounts of the effects of MDMA in patients during therapy sessions. Among these
reports, patients described elevated mood, feelings of closeness and intimacy,
increased empathy, self-examination and insight, suppressed appetite, and jaw
clenching (Greer & Tolbert, 1986; Shulgin & Nichols, 1978). Following the DEA’s
placement of MDMA as a Schedule I drug in 1985 and prior to the FDA’s approval of
research with MDMA in 1992, only surveys could be conducted to investigate the
effects of MDMA (Bravo, 2001). These reports (Grinspoon & Bakalar, 1986;
Peroutka et al., 1988; Siegal, 1986; Solowij et al., 1992) continued to include similar
descriptions of the subjective effects of MDMA, but also included recreational users.
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Additional aspects o f the subjective effects of MDMA were added by reports of
recreational users, such as alterations in color perception (Cami et al., 2000;
Vollenweider et al., 1998), though hallucinations were generally only reported at very
high doses (Siegal, 1986; van de Wijngaart, Braam, de Bruin, Fris, Maalste, &
Verbraeck, 1999). These reports indicated that the subjective effects of MDMA
shared both stimulant-like and hallucinogen-like properties. Indeed, MDMA is
currently classified into the traditional drug classes as both a stimulant and a
hallucinogen.
One method in which to investigate the subjective effects of psychoactive
compounds under controlled conditions is the drug discrimination assay. Drug
discrimination procedures are designed to systematically investigate aspects of the
subjective effects of psychoactive compounds, using humans and non-humans, by
providing data regarding the stimulus properties of drugs.

The Drug Discrimination Assay

An Overview
The drug discrimination procedure is a popular assay used to classify the
stimulus properties o f psychoactive drugs. In this procedure, psychoactive drugs
serve as discriminative stimuli. In the presence of the drug stimulus a specific
behavior is reinforced, while in the absence of the drug stimulus another behavior is
reinforced. Drug discriminations typically employ a two-lever procedure where
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subjects receive a psychoactive drug or vehicle (e.g., saline). In order to receive a
reinforcer (e.g., a food pellet in a food deprived subject), subjects are required to
perform one behavior in the presence of the psychoactive drug (e.g., lever press on a
particular lever) and a different behavior in its absence (e.g., lever press on a different
lever). One method is to employ a resetting fixed-ratio schedule of reinforcement
whereby a set number of consecutive responses (e.g., 10 lever presses) are required to
obtain reinforcement. That is, a subject is required to respond on the conditionappropriate lever 10 consecutive times without responding on any other lever in order
to obtain a reinforcer, if the subject responds on a different lever prior to completing
the 10 consecutive responses, the ratio is reset. A subject may be said to have learned
the discrimination task when condition-appropriate responding prior to the
presentation of the first reinforcer is 80% or better for a predetermined number of
consecutive sessions (e.g., 8 out of 10 consecutive sessions). Drug discrimination
methods may also employ other schedules or reinforcement, such as fixed- or
variable-interval schedules. In a review of drug discrimination methodology,
Stolerman (1993) reported that not only do most studies use a fixed-ratio schedule of
reinforcement but that these schedules tend to support stronger stimulus control than
do other schedules.
Once a discrimination is established, other psychoactive drugs are often
administered to examine whether novel drugs produce similar discriminative stimulus
effects to the training drug. Generally, in a two-lever discrimination, a novel drug is
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said to “substitute” if the resulting lever-pressing behavior following administration is
80% or greater on the drug-appropriate lever. That is, the subject has generalized the
stimulus effects of the novel compound to the stimulus effects of the training drug.
Additionally, an antagonist may be administered prior to the training drug. An
antagonist is said to “block” the stimulus effects of the training drug if the resulting
lever-pressing is 80% or greater on the vehicle-appropriate lever (Appel, Baker,
Barrett, Broadbent, Michael, Riddle, & Van Groll, 1991).
It is sometimes the case that compounds produce asymmetrical generalization.
This results when “drug A” will substitute for “drug B” but “drug B” will not
substitute for “drug A”. This may result because “drug B” has multiple
pharmacological actions that include those of “drug A”. Conversely, “drug A” has a
relatively specific pharmacological effect that is only one aspect of the stimulus
produced by “drug B”. Compounds with multiple pharmacological actions (i.e.,
complex stimuli) have been described as being either “conditional” or “redundant”
(Grant, 1999; Mackintosh, 1974). A conditional discrimination of complex stimuli is
said to require all components of the cue to be present for stimulus generalization to
occur, while a redundant discrimination results in stimulus generalization when any
component of the complex stimulus is presented (Grant, 1999; Jarbe, Hiltunen, &
Swedberg, 1989). It has been illustrated that when drugs from different
pharmacological classes are combined together for use as a discriminative stimulus, a
redundant discrimination is formed (Grant, 1999; Mariathasan, Garcha, & Stolerman,

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

18

1991; Stolerman, Rauch, & Norris, 1987; Stolerman & White, 1996). That is, each
compound administered individually will substitute for the training stimulus produced
by the mixture of both compounds. This is important to consider when using
complex discriminative stimuli and when describing asymmetrical generalizations
between compounds.
In order to ensure the subjects are continuing to reliably discriminate the
training conditions between testing sessions, a measure o f terminal accuracy is
usually employed. Terminal accuracy is generally measured by the percent of
condition-appropriate responses prior to delivery of the first reinforcer during training
sessions. For example, in a resetting FR 10 schedule, any number of responses may
be made prior to 10 consecutive responses on the condition-appropriate lever. It is
the percentage of the total number of responses on the condition-appropriate lever,
prior to the presentation of reinforcement, which defines terminal accuracy. This
measurement is generally referred to as “percent first FR responding”. Requiring
subjects to maintain a percent condition-appropriate first FR above 80%-90% for the
condition-appropriate lever between testing sessions is the general standard for
adequate stimulus control.

Historical Beginnings
The early beginnings of the drug discrimination procedure can be traced back
to the 1830’s when descriptions of state-dependent learning (SDL) where being
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reported by clinicians. These clinical cases generally were descriptions of patients
who were unable to recall events that occurred while they were intoxicated but once
intoxicated again, where able to recall the events; or patients who were unable to
recall events that occurred during some sort of paroxysmal event (Overton,
Rosecrans, & Barry, 1990). In 1892, in a book entitled “Diseases o f Memory”, Ribot
described the relationship between the physiological state of the body and memory
recall as being mediated by the “organic sensations” occurring at the time of memory
formation. These “organic senses” later became known as “interoceptive stimuli”.
Ribot also considered a non-drug state as equally important in the process of memory
retrieval, asserting that just as memories formed during drug states are difficult to
recall during non-drug states, memories formed during non-drug states are difficult to
recall during drug states (Overton et al., 1990).
From 1892 up until the early 1900’s, the concept of SDL appeared in writings
of memory theorists and researchers, including Combe, Semon, Coriat and Prince
(Overton et al., 1990). However, SDL virtually disappeared in descriptions of
memory processes around 1925. This is the time when psychoanalysis emerged as a
popular school of thought (Gray, 1994).
Within psychoanalysis theory, Sigmund Freud described three processes as
being responsible for all aspects o f behavior, including learning. The id, ego, and
superego are the terms used to represent these processes. Simply put, the id was
thought to be responsible for our desire for gratification, the ego for repression of
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memories as a “defense mechanism” used by our unconscious in an attempt to avoid
potential unpleasant emotional states, and the superego represented society’s morals.
Within this framework it was thought that memory formation and learning was a
result of an interaction between these three internal processes in the
“unconsciousness”. The idea that memory retrieval is mediated by a portion of our
unconscious “mind” left little room for SDL as a determinant of memory retrieval.
Psychoanalysis became a popular school of thought and unfortunately, SDL
effectively disappeared from experimental psychology and did not show up again
until the late 1930’s.
In 1937, Girden and Culler reported a curare and no-drug induced dissociation
in dogs. Essentially, by illustrating this curare induced dissociation Girden and Culler
exemplified what is now known as drug-induced state dependent learning. It is this
area of research that would become known as drug discrimination and lead the way
for experimental work (Overton et al., 1990).
The first actual report of a drug discrimination study was by Conger (1951).
He was attempting to study how alcohol affects approach and avoidance behavior in
rats. He reported having trained the avoidance response under no-alcohol conditions
and found a difference in later performance between no-alcohol and alcohol groups.
He then noted that while there is a difference between the groups, it is possible that
“the avoidance response might be due solely to a change in the animal’s condition
(regardless of the direction of change) rather than to any specific effect of alcohol
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because it seems likely that a change from sobriety to inebriation (or vice versa)
produces a change in the animal’s stimulus situation” (Conger, 1951, p. 15). He then
reported having successfully trained his subjects to approach under an alcohol
condition and avoid under a no-alcohol condition, and vice versa. Interestingly,
Conger made no statement as to how this SDL took place; he simple reported it had
occurred.
In 1966, Overton reported an important development; he demonstrated that
two drugs (atropine and pentobarbital) produced distinctly different stimulus effects.
This led to additional studies in 1971 where Overton reported several types of drug
that were discriminated from each other, and from a no-drug state. This
demonstration led to what are now called “generalization gradients”. That is, drugs
that are part of a specific class (e.g., stimulants) will generally produce similar
stimulus effects and drugs that are defined as part of different classes (e.g. a stimulant
and a hallucinogen) will produce distinctly different stimulus effects (Barry, 1974).
This is demonstrated by the general finding that the administration of drugs from the
same class will result in drug-appropriate responding and the administration of drugs
from different pharmacological classes will produce responding on the lever
correlated with the absence of drug.
During the 1960’s and 1970’s many researchers began using variations in the
approach/avoidance procedure to study the stimulus effects of drugs. The T-maze
was one such procedure. In this assay a subject is reinforced for entering one side
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following drug administration and the opposite side in the absence of the drug. In this
way, the rate suppressing effects that may influence the interpretation of single
response go-no go procedures (i.e., approach/avoidance) were minimized. Another
major change was the use of operant lever-pressing behavior, reported to be sensitive
to even lower doses of drugs then the T-maze (Kubena & Barry, 1969). Then in 1975
the fixed ratio (FR) schedule o f reinforcement was introduced into drug
discrimination research by Colpaert and his collegues. The advantage of the FR
schedule is a higher level of accuracy (Overton et al., 1990). Most recently,
researchers have begun using drug versus drug discriminations, and three-lever
procedures where subjects are trained to discriminate between two drugs and a
vehicle. It appears that these are more sensitive assays with which to study the
stimulus effects of psychoactive drugs (Stolerman, 1993), particularly those with
multiple pharmacological actions (Baker & Taylor, 1997).
The popularity and use of the drug discrimination assay has grown profoundly
since its inception. Researchers have used the assay to study a vast array of centrally
acting compounds. Indeed, an entire database of published drug discrimination
studies (i.e., the drug discrimination bibliography) since 1970, created by I.P.
Stolerman, can be accessed via the World Wide Web.
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Contributions of the Drue Discrimination Assay
The drug discrimination assay is used by researchers for a variety of purposes.
These include describing the stimulus properties of an assortment of psychoactive
substances, investigating underlying neurochemical processes of these substances,
indexing abuse potential of drugs, investigating the time-course of drug effects, and
aiding new drug development (Colpaert, 1986; 1999; Holtzman, 1990).
Using the drug discrimination procedure, the stimulus properties of drugs can
be described as “similar” or “dissimilar”. This is useful when classifying
psychoactive substances (i.e., stimulants, hallucinogens, etc.). This sort of
elementary description of drugs is a useful starting point for investigation of centrally
acting compounds.
Although there are assays which are traditionally used to measure the abuse
potential of drugs (e.g., self-administration, progressive ratio schedules), the drug
discrimination assay may be used to examine aspects of the abuse potential of drugs
(Glennon, 1991). For example, a novel compound substituting for cocaine in a drug
discrimination procedure may be interpreted as a preliminary indication of abuse
potential. One might then pursue the issue in assays specifically designed to measure
abuse potential.
The drug discrimination assay also makes important and unique contributions
to the development of new therapeutic agents (Meert & Awouters, 1990). For
example, it has been reported that ( 5 -HT2) antagonists may produce anti-anxiety and
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antidepressant properties (Glennon, 1991). Potential therapeutic compounds may be
identified by testing them for their antagonist properties in 5 -HT2 agonist
discrimination designs.
The drug discrimination assay may also be used to examine the underlying
neurochemical mechanisms involved in producing the stimulus properties of drugs.
This is an important aspect for potential treatments of drug overdose, as well as the
development of agents to treat drug addiction. A compound that is a known
antagonist for a specific receptor site that blocks the stimulus effects of an abused
drug may be helpful in treating drug addiction, or aid in the development of agents to
treat an overdose.
Limitations of the Drug Discrimination Assay
A major limitation of the drug discrimination assay is the extensive amount of
time required to conduct a single study. A typical two-lever procedure generally
requires 20-40 training sessions while the more complex three-lever design has been
reported to require between 80-100 sessions (Baker & Taylor, 1997; Goodwin &
Baker, 2000; Overton, 1978). The time requirement to conduct drug discrimination
research is further prolonged by the methodological consideration that once the
discrimination is established, at least one training day for each stimulus condition
must occur between test days. Thus, in a two-lever discrimination there are at least
two training days between test sessions and this is increased to a minimum of three
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training days for the three-lever design. Essentially, a typical two-lever study
requires a minimum of nine to twelve months to complete while the more complex
three-lever design requires between twelve and fifteen months.
A second methodological consideration in drug discrimination research is data
interpretation. The nature of the drug discrimination assay assures that regardless of
the stimulus properties of a particular compound, subjects will respond. As noted
above, a novel drug is said to “substitute” if the resulting lever-pressing behavior
following administration of a novel compound is 80% or greater on the drugappropriate lever. Conversely, an antagonist is said to have “blocked” the stimulus
effects of the training chug if the resulting lever-pressing is 80% or greater on the
vehicle-appropriate lever. However, data interpretation when lever-pressing is
between 20% and 80% on a single lever, what is referred to as “partial substitution”
or “partial blockade”, is problematic. Some have suggested that this may be
interpreted as the subject responding on a sort of continuum o f chug effect where the
percent responding represents a description of the level of chug effect but this has not
been experimentally tested (Colpaert, 1988) and so cannot be assumed to be true.

Drug Discrimination and MDMA
As described earlier, the drug discrimination assay is a useful tool in drug
abuse research and is used extensively with psychoactive chugs of abuse, particularly
to classify drugs as similar or dissimilar. It is critical to examine MDMA in the drug
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discrimination assay because of its reported complex and relatively unknown
mechanisms o f action. Indeed, MDMA has been extensively investigated using the
traditional two-lever drug discrimination method; however, these reports have yielded
conflicting results. There are relatively few studies that have examined the stimulus
properties of MDMA using a three-lever procedure.
In 1987 Schechter reported that MDMA produced stimulus control in rats
trained to discriminate MDMA from saline using a FR 10 schedule o f food
reinforcement. He also reported that MDMA substituted for itself in a dosedependent manner. Prior to this published account, MDMA had only been used to
test for substitution in studies examining the stimulus control o f other drugs. For
example, Schechter (1986) reported that MDMA substituted for the serotonin agonist
fenfluramine, the indirect dopamine agonist /-cathinone, and the serotonin agonist
tetrahydo-B-carboline (THBC). Schecther concluded that the discriminative stimulus
effects of MDMA were probably mediated via indirect-acting dopaminergic agonist
properties, and also by acting upon a subtype of serotonin receptor, probably the 5HT2 receptor subtype. This conclusion was supported by other studies as well
(Broadbent, Appel, Michael, & Ricker, 1992).
However, there are conflicting reports regarding the substitution of MDMA
for the known dopamine agonist, d-amphetamine. With d-amphetamine (2.0 mg/kg)
as the training drug, Evans and Johanson (1986) reported that MDMA (3.0 mg/kg)
substituted for d-amphetamine in pigeons responding under a FR 30 schedule of
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reinforcement. However, this study used a total of only three subjects. Glennon and
Young (1984) also reported that MDMA (2.25 mg/kg) would also generalize to damphetamine (1.0 mg/kg) in rats trained to discriminate d-amphetamine from saline.
Subjects were trained to respond under a VI 15s schedule of reinforcement. Glennon
e t al used four subjects, but only three completed the test session at the dose which
produced complete substitution (2.25 mg/kg). Conversely, Oberlander and Nichols
(1988) reported that MDMA (2.63 mg/kg) did not substitute for d-amphetamine (1.0
mg/kg) in rats (n=14) trained to discriminate d-amphetamine from saline under a FR
50 schedule of reinforcement. In addition, Oberlander et. al also reported that damphetamine (1.2 mg/kg) did substitute for MDMA (1.75 mg/kg) when MDMA was
the training stimulus, but was disruptive in seven of the thirteen rats tested. Schechter
(1989) trained eight rats to discriminate MDMA (1.5 mg/kg) from saline under a FR
10 schedule of reinforcement. He reported that d-amphetamine (0.8 mg/kg) only
partially substituted for MDMA. Glennon and Misenheimer (1989) also reported that
d-amphetamine (1.0 mg/kg) only partially substituted for MDMA (1.5 mg/kg) in rats
(n=4) trained to discriminate MDMA from d-amphetamine under a VI 15s schedule
of reinforcement.
There are also conflicting reports of the substitution of MDMA to serotonin
agonists, such as LSD and fenfluramine. Schechter (1986) reported that MDMA (2.0
mg/kg) substituted for the training drug fenfluramine (2.0 mg/kg) in rats (n=10)
trained to discriminate fenfluramine from vehicle under a FR 10 schedule of
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reinforcement. Schechter (1998) also reported that LSD (0.12 mg/kg) substituted for
MDMA (1.5 mg/kg) in a similar procedure. There is also at least one study that
reported nearly complete (78%) substitution of LSD (0.16 mg/kg) for MDMA (1.75
mg/kg) (Oberlander & Nichols, 1988) in a two-lever procedure. Norfenfluramine
(1.4 mg/kg), another 5-HT agonist, has also been reported to substitute for MDMA
(1.5 mg/kg) in rats (Schechter, 1989). However, Callahan and Appel (1988) reported
that MDMA did not substitute for LSD in rats.
Although there are relatively few studies which have examined the stimulus
properties of MDMA in more complex discriminations (i.e., three-lever or drug vs.
drug), Evans, Zacny, and Johanson (1990) trained five pigeons to discriminate
various doses of d-amphetamine, fenfluramine, and saline using a three-lever
procedure and a FR 30 schedule of reinforcement. In the three subjects tested, they
reported that MDMA substituted for d-amphetamine in two of the subjects and for
fenfluramine in the third subject. Baker and Taylor (1997) also examined the
stimulus properties of MDMA in two separate, three-lever drug discrimination
experiments. In the first, rats were trained to discriminate d-amphetamine (1.0
mg/kg), mescaline (12.5 mg/kg), and saline under a FR 20 schedule of reinforcement.
Stimulus generalization tests with (+)-MDMA did not result in complete substitution
for d-amphetamine, but resulted in mostly saline-appropriate responding, with some
responding on the mescaline-appropriate lever. Administration of (-)-MDMA
produced 78% mescaline-appropriate responding. In the second experiment, Baker
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et. al trained rats to discriminate d-amphetamine (1.0 mg/kg), LSD (0.08 mg/kg), and
saline They reported that neither isomer of MDMA substituted for d-amphetamine,
and actually produced some responding on the LSD-appropriate lever, though not
enough to represent full substitution.
In an attempt to further investigate the stimulus properties of MDMA,
Goodwin and Baker (2000) trained rats to discriminate between d-amphetamine (1.0
mg/kg), MDMA (1.5 mg/kg), and saline under a FR 10 schedule o f reinforcement.
We reported that all the subjects were able to learn the discrimination and that damphetamine produced dose-dependent increases in d-amphetamine-appropriate
responding and MDMA produced dose-dependent increases in MDMA-appropriate
responding. We also demonstrated that the administration of LSD resulted in dosedependent increases in MDMA-appropriate responding with almost complete
substitution for MDMA (i.e., 78% MDMA-appropriate responding) at the two highest
doses tested (0.08 and 0.16 mg/kg). The administration of cocaine resulted in dosedependent increases in d-amphetamine-appropriate responding, with complete
substitution at the highest dose tested (10 mg/kg). Additionally, fenfluramine
substituted for MDMA, as did both isomers of MDA, while the 5 -HT2 antagonist
pirenperone only partially blocked the stimulus effects of MDMA. These results are
particularly significant because they are definitive in that subjects were able to learn
to discriminate between MDMA and d-amphetamine, leaving little doubt that
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although MDMA is structurally related to d-amphetamine, the discriminative stimulus
effects of these two compounds are clearly different.
It also appears that in that procedure, MDMA served as a redundant
discriminative stimulus rather than a conditional stimulus. That is, the compound
stimulus effects produced by MDMA acting as both a serotonin and dopamine agonist
were differentiated from the relatively specific stimulus effects d-amphetamine
produced by its actions as a dopamine agonist. This if further supported by the fact
that serotonin agonists (e.g., LSD, fenfluramine, and MDA) produced dose-dependent
increases in MDMA-appropriate responding. If MDMA had served as a conditional
stimulus it would follow that all components of the MDMA stimulus would have to
be present for the stimulus effects o f a drug to substitute for the stimulus effects of
MDMA in this procedure and drugs acting relatively specifically as serotonin
agonists would not substitute for MDMA in this procedure. It also follows then, that
rats trained to discriminate MDMA from a serotonin agonist (e.g., LSD) in a similar
procedure would generalize the stimulus effects of dopamine agonists (e.g., damphetamine) to MDMA.
It has also been suggested that subjects rely on the most salient part of
compounds with complex stimulus properties in order to discriminate them (Wood,
Lai, Yaden, & Emmett-Oglesby, 1985). It appears that the serotonergic effects of
MDMA become more salient in maintaining stimulus control when animals are
trained to discriminate both d-amphetamine and MDMA. Thus, it is also possible that
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the dopaminergic effects of MDMA could become more salient if rats were trained to
discriminate between MDMA and a serotonergic compound, such as LSD. If this is
the case, then one would expect d-amphetamine to substitute for MDMA in these
animals.

Rationale for the Present Study

The present study was designed to further investigate the discriminative
stimulus effects of MDMA. Specifically, since MDMA is classified as both a
stimulant and a hallucinogen, and it has been established that rats can discriminate
between d-amphetamine and MDMA in a three-choice procedure, the present study
sought to determine if rats could be trained to discriminate between a hallucinogen
(i.e., LSD) and MDMA in a similar three-lever procedure. Additionally, if such a
discrimination could be established in rats, this study sought to determine what
pharmacological actions of MDMA were most salient in maintaining stimulus control
in these animals.
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CHAPTER II
METHODS

Subjects
Twelve experimentally naive Sprague-Dawley rats (Harlan Breeding
Laboratories, Indianapolis, IN) approximately 60 days old at the beginning of the
study, and weighing between 250 and 300 g were used as subjects. Subjects were
individually housed in plastic shoebox cages in a colony maintained on a 12-h light
(0700 to 1900)/12-h dark cycle, at relatively constant temperature (20-22 ° C) and
humidity levels (50-60%). In the home cages, subjects were allowed free access to
water while food intake was restricted to maintain body weights between 85% and
90% of their free feeding weights for the duration of the study. The experimental
protocol was reviewed by the Institutional Animal Care and Use Committee of
Western Michigan University and subjects were maintained according to the general
principles of animal husbandry outlined by the National Institutes on Drug Abuse.

Materials

All training and testing procedures were conducted in eight standard operant
test chambers (MED Associates, Inc., Georgia, VT) measuring 30 x 31 x 24 cm,
maintained in sound- and light-attenuating cubicles. The chambers were equipped
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with three retractable levers on the front panel, a 28-V house light located on the rear
panel, and a food pellet delivery mechanism located above the center lever.
The (±)-MDMA, (+)-LSD, d-amphetamine sulfate, and fenfluramine
hydrochloride were obtained from the National Institute on Drug Abuse (Rockville,
MD). The MDL-100,907 was generously donated by Dr. Meltzer (Vanderbilt
University) and the haloperidol was obtained from Sigma (St. Louis, MS). The (±)MDMA, (+)-LSD, d-amphetamine, and fenfluramine were dissolved in 0.9%
bacteriostatic sodium chloride and administered intraperitoneally 15 min prior to
training and testing sessions. The MDL-100,907 was dissolved in sterile water and
administered 30 min prior to testing. The haloperidol was dissolved in sterile water
with drops of lactic acid added until the drug went into solution, and administered 45
minutes prior to testing. All drugs were administered in an injection volume of 1
ml/kg.

Training Procedures

An autoshaping procedure was used for the first week of the experiment.
Subjects received between 5 and 6 one hour sessions where no substances were
administered, no levers were present in the chamber, and food pellets were delivered
on a fixed-time 60 sec (FT 60”) schedule of food delivery. Subsequently, errorless
discrimination training was employed where only the condition-appropriate lever was
present for alternate 20 min training sessions of saline and each drug condition. This
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was continued until each subject was exposed to at least four errorless training
sessions for each of the three conditions. During the errorless training sessions a
fixed-ratio one (FR 1) schedule of reinforcement was used.
Following the errorless training procedures, all three levers were presented
and discrimination training began with a FR 1 schedule of reinforcement during daily
20 min training sessions. The ratio was gradually increased to 10 as responding
became stable. The terminal schedule of reinforcement was a resetting FR 10. That
is, reinforcement was contingent on 10 consecutive responses on the conditionappropriate lever, responses on any other lever reset the response counter and
reinforcement was not delivered until 10 consecutive responses were made on the
condition-appropriate lever. Subjects were able to obtain an unlimited number of
reinforcers during the 20 min training sessions. With the administration of MDMA,
half of the subjects were reinforced for responses on the left lever and half were
reinforced for responses on the right lever. The conditions were reversed for the
administration of LSD. Under saline conditions, all subjects were reinforced for
responses on the center lever. In order to reduce the effects of olfactory cues between
animals in the operant chambers, all levers were wiped with isopropyl alcohol
between training sessions (Extance and Goudie, 1981). Additionally, the order in
which subjects were run during the daily sessions was altered randomly. Training
sessions were conducted 6 days a week at approximately the same time each day.
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Testing Procedures

Once subjects met a pre-determined criterion for discrimination (80% of
responses on the condition-appropriate lever prior to the delivery of the first
reinforcer for at least 8 out of 1 0 consecutive training sessions), testing procedure
were implemented. Test sessions were similar to training sessions except that no
reinforcers were delivered and the animals were removed from the chambers
immediately upon completion of 10 consecutive responses on any lever. Test
sessions were conducted once or twice per week in place of training sessions,
provided that during training sessions the animals maintained 80% or better
condition-appropriate responding prior to the delivery of any reinforcers under each
stimulus condition.
Stimulus generalization tests were conducted with three doses of each training
drug (MDMA 0.375-1.5 mg/kg; LSD 0.02-0.08 mg/kg), d-amphetamine (0.50-2.0
mg/kg), fenfluramine (0.50-2.0 mg/kg), and the combination of fenfluramine (0.250.50 mg/kg) and d-amphetamine (0.25-1.0 mg/kg). Antagonist tests were conducted
with the 5 -HT2 antagonist MDL-100,907 (0.0325-0.50 mg/kg) in combination with
the training dose of MDMA (1.5 mg/kg) and in combination with the training dose of
LSD (0.08 mg/kg). Additionally, haloperidol (0.1-0.4 mg/kg) was administered in
combination with the training dose of MDMA.
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Data Analysis

Initially, all subjects received the same stimulus for training sessions and the
criterion for acquisition of the discrimination was 80%-100% stimulus appropriate
responding prior to the delivery of the first reinforcer for eight out of ten consecutive
training sessions. However, following the initiation of dose-response curves for the
training drugs (i.e., MDMA and LSD) it appeared that stimulus control was
inadequate. Despite methods used to reduce olfactory cues, it is possible that some
subjects were using residual olfactory cues, or some other cue, during training
sessions. Therefore, rather than continuing to administer the same training stimulus
to all subjects, the three stimulus conditions were varied across subjects starting at
training sessions 137. In this way, any residual olfactory cues were not reliable
prompts for identification of the lever correlated with the presentation of
reinforcement during any given training session. Following this change, all subjects
were required to again meet the criterion for discrimination. The number of sessions
to criterion, both before and after this procedural change, is presented for visual
analysis.
A dose-response curve was generated for each compound tested in order to
depict the percent of total responses on each lever for each dose tested, as well as the
overall response rate at each dose. A group mean was calculated for each measure at
each dose. Only the data from subjects who emitted at least ten responses during
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testing sessions were included to calculate the percentage of responses on each lever
data. The data from all subjects were used to calculate response rates. A one-way
analysis o f variance (ANOVA) was used to analyze stimulus generalization data and
response rate for each compound tested. Complete stimulus generalization was
defined as at least 80% responding on either the (±)-MDMA or (+)-LSD appropriate
lever. Complete stimulus blockade was defined as at least 80% responding on the
saline-appropriate lever. For compounds that produced stimulus generalization or
stimulus blockade, nonlinear regression analyses were calculated to determine ED50S.
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CHAPTER III

RESULTS
Sessions to Criterion

All 12 subjects acquired the discrimination o f LSD and MDMA. Following
the discovery that stimulus control was not reliably maintained when the training
doses were assessed during initial stimulus generalization tests, the stimulus
conditions during the daily training sessions were varied for individual subjects. For
example, subjects 1 through 6 may have received MDMA as the training stimulus for
the same training session that subject 7 through 12 were administered LSD. Figure 1
illustrates the number o f sessions to meet the preset criterion for discrimination for
each individual subject, both before and after this procedural change. The mean
number of sessions for the subjects to initially meet the discrimination was 49 (SEM
= 3.18, range = 35 to 6 8 ). Upon resuming training with differing training stimuli
among subjects, the mean of the total number of sessions to criterion (i.e., including
the original number to meet the preset criterion) was 153 (SEM = 2.86, range = 145
to 174).

38
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Stimulus Generalization

Figure 2 represents the results of stimulus generalization tests with MDMA
(0.375-1.5 mg/kg). There were dose-dependent increases in MDMA-appropriate
responding with virtually no LSD-appropriate responding across doses. The ED50 for
MDMA was 0.97 mg/kg (95% confidence intervals: 0.2488-1.694). There were
significant dose-dependent increases in the percentage of MDMA-appropriate
responding across doses [F(3t43)=21.18, p<.0001] but no differences in response rates
across doses [F(3i43) = 1.09, p>.05].
The dose-response data for LSD (0.02-0.08 mg/kg) are presented in Figure 3.
The ED50 for LSD was 0.038 mg/kg (95% confidence intervals: 0.006-0.223). There
were significant dose-dependent increases in LSD-appropriate responding
[F(3,43)=23.77, p<.0001] with no MDMA-appropriate responding at 0.04 mg/kg nor
the training dose, 0.08 mg/kg. However, there was a small amount (13%) of MDMAappropriate responding at 0.02 mg/kg of LSD. Response rates did not differ across
doses [F(3i43) = 0.19, p>.05].
Figure 4 represents generalization tests with d-amphetamine (0.25-2.0 mg/kg).
There were significant dose-dependent increases in MDMA-appropriate responding
[F(4,22)=3 . 1, p<.05] and dose-dependent decreases in saline-appropriate responding.
However, d-amphetamine did not completely substitute for MDMA at any of the
doses tested. There was MDMA-appropriate responding at both the 1.0 mg/kg and
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2.0 mg/kg doses with the greatest percentage of MDMA-appropriate responding at
2.0 mg/kg, (60% MDMA-appropriate responding), the highest dose tested. There
were significant dose-dependent decreases in the rate of responding, with severe rate
suppression at the highest dose tested [F(4, 29)= 3.028, p<.05]. Six animals were tested
at the 2 . 0 mg/kg dose, the highest dose administered, and only three completed the
test. Due to the severe suppression of response rate, higher doses were not tested.
Two subjects were administered the 0.25 mg/kg dose for later comparison to the
combinations of d-amphetamine and fenfluramine.
The results of substitution tests with fenfluramine (0.25-2.0 mg/kg) are
presented in Figure 5. As illustrated, there are significant dose-dependent increases in
MDMA-appropriate responding [F(5^3)=19.41, p<.001], with complete substitution at
the highest dose tested, 2.0 mg/kg. The ED 50 for fenfluramine was 1.42 mg/kg (95%
confidence intervals: 0.927-1.91). There was not a significant amount of LSDappropriate responding at any o f the doses tested, though at the

1 .0

mg/kg dose there

was 20% LSD-appropriate responding. There were no significant differences across
doses with respect to response rate [ F ^ ) = 1.01, p>.05].
Figure 6 illustrates the percentage of MDMA-appropriate responding with
doses of d-amphetamine (0.25, 0.50,1.0 mg/kg) and fenfluramine (0.25,0.50 mg/kg)
administered in combination. This was done to examine the possibility that these
compounds may have synergistic effects. Included in Figure 6 is the percentage of
MDMA-appropriate responding for fenfluramine and d-amphetamine administered
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alone such that they may be compared to the administration of the combinations of
both drugs. One combination (0.50 mg/kg d-amphetamine and 0.50 mg/kg
fenfluramine) resulted in complete substitution for the MDMA cue. However, the
differences in MDMA-appropriate responding across the doses of d-amphetamine
(0.25-1.0 mg/kg) was not quite significant [F(2,i7)=3.63, p=.051] when combined with
0.25 mg/kg of fenfluramine. The combination of 1.0 mg/kg d-amphetamine and 0.25
mg/kg fenfluramine produced nearly complete substitution for MDMA (79%).

The

differences in MDMA-appropriate responding was not significant when 0.50 mg/kg
of fenfluramine was combined with d-amphetamine (0.25-1.0 mg/kg) [F(2,i7)=1.83,
p<.05]. There was virtually no LSD-responding at any of the dose combinations
tested. There were dose-dependent decreases in rate of responding, with the lowest
response rates occurring at the 1.0 mg/kg of d-amphetamine in combination with 0.25
and 0.50 mg/kg of fenfluramine. Although the response rate was significantly
suppressed [F(5, 17) = 3.86, p>.05], all subjects completed the test sessions at all the
dose combinations tested.
The administration of MDL-100907 (0.03125-0.50 mg/kg) prior to the
training dose o f MDMA (1.5 mg/kg) did not produce dose-dependent decreases in
MDMA-appropriate responding (Figure 7). In fact, MDL-100907 administration
produced the lowest percentage of MDMA-appropriate responding (28% MDMAappropriate responding) at 0.0625 mg/kg, but this was neither the lowest nor the
highest dose of MDL-100907 tested. The percentage o f MDMA-appropriate
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responding when .0625 mg/kg of MDL-100907 was given prior to MDMA was
significantly different from the percentage observed when vehicle was given prior to
MDMA [F(5>4i)=2.76, p<.05]. Although the rate of responding decreased in a dosedependent fashion, the difference across doses was not significant [F(5>41) = .47,
p>.05].
Conversely, the administration o f MDL-100907 (0.03125-0.50 mg/kg) in
combination with the training dose of LSD (0.08 mg/kg) resulted in complete
blockade of the LSD stimulus [F(5>30)=2 6 .8 1 , pc.OOOl] at all of the doses of MDL100907 tested (Figure 8 ). LSD-appropriate responding occurred in only one subject
at one dose (0.25 mg/kg). The differences in response rate across doses was not
significant [F ^ o )= 1-08, p>.05].
The administration of haloperidol (0.1-0.4 mg/kg) in combination with the
training dose of MDMA (1.5 mg/kg) did not result in any decreases in MDMAappropriate responding (Figure 9). That is, only MDMA-appropriate responding was
observed at all of the doses of haloperidol tested. Haloperidol also produced a
significant decrease in response rate [F(3,l 1) = 4.85, p<.05]. Due to the advanced
age of the subjects, only three subjects were tested on the haloperidol and MDMA
combination.
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Figure 1. Illustration of the Number of Sessions Required to Establish the
LSD/MDMA/Saline Discrimination (N=12).
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CHAPTER IV

DISCUSSION

The present results support the notion that, despite its classification as both a
stimulant and a hallucinogen, MDMA produces complex stimulus effects that are
distinctly different from those of other psychostimulants and hallucinogens. Indeed,
it has been proposed that MDMA and similar amphetamine analogs belong to a
separate drug class called “etactogens” (Nichols, 1986). Previous studies have
concluded that the stimulus properties of MDMA are mediated through both
serotonergic and dopaminergic actions (Glennon, Higgs, Young, & Issa, 1992;
Malberg & Bonson, 2001; Schechter, 1989), though the relationship between these
actions and the resulting stimulus effects is not well understood. The relative
importance of dopaminergic vs. serotonergic actions in maintaining stimulus control
by MDMA appears to depend on the drug discrimination methods employed.
Moreover, conflicting results from previous drug discrimination studies with MDMA
are likely due to methodological differences among laboratories.
It is well established that the stimulus properties of d-amphetamine are
primarily mediated via changes in dopamine (Goudie, 1991; Ho & Huang, 1975;
Nielsen & Jepsen, 1985; Woolverton, 1984; Yokel & Wise, 1976). It is also welldocumented that the stimulus effects of LSD are primarily mediated through actions
on serotonin (Bonson, Buckholtz, & Murphy, 1996; Cameron & Appel, 1973;
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Glennon, Rosecrans, & Young, 1982; Sadzot, Baraban, Glennon, Lyon, Leonhardt,
Jan, & Titeler, 1989; Trulson, Ross, & Jacobs, 1976). Baker and Goodwin (2000)
recently demonstrated that rats could be trained to dissociate the effects of damphetamine from those of MDMA in a three-lever assay. One may conclude that, in
that procedure, serotonergic actions became a more salient feature of MDMA’s
discriminative stimulus effects relative to its dopaminergic actions. This is further
supported by the observation that the administration of other serotonin agonists (i.e.,
LSD and fenfluramine) resulted in dose-dependent increases in MDMA- appropriate
responding, while cocaine, a dopamine agonist, produced full substitution for damphetamine. Therefore, it is possible that the dopaminergic effects of MDMA could
become more salient if rats were trained to discriminate between MDMA and a
serotonin agonist such as LSD. However, the present results do not support this
hypothesis.
In the present study, rats were successfully trained to discriminate between
LSD and MDMA. All subjects were required to meet the discrimination criterion
twice because stimulus control was not adequately maintained following initial doseresponse determinations with the training drugs. Although the experimental
chambers were wiped with isopropyl alcohol between groups, it is possible that
stimuli from previous subjects in the same chamber were contributing to the initial
development of stimulus control. Thus, the three stimulus conditions (i.e., MDMA
LSD, and saline) were varied across subjects so that any olfactory cues present in the
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experimental chambers were not reliable prompts for identifying the appropriate lever
during training sessions. Following this change, subjects were again required to meet
the criterion for discrimination.
It is apparent from the total number of sessions required to meet the
discrimination criterion (80% of responses on the condition-appropriate lever prior to
the delivery of the first reinforcer for at least 8 out of 10 consecutive training
sessions) that the stimulus effects of LSD and MDMA are difficult to distinguish.
Indeed, a typical two-lever discrimination can require between 30 and 60 training
sessions to establish while the present study required a mean of 153 sessions to
establish and reliably maintain the discrimination. Additionally, although all 12
subjects met the criterion for discrimination, one of them did not maintain the
discrimination and was never tested for stimulus generalization. None-the-less, all the
subjects did meet the criterion for stimulus control and both training doses produced
substitution in the 11 subjects tested.
Although subjects did learn to discriminate between MDMA and LSD, damphetamine failed to substitute for MDMA, while fenfluramine produced full
stimulus generalization to MDMA. This supports previous reports that the serotonin
releaser fenfluramine (Goodwin & Baker, 2000; Schechter, 1986) and its metabolite,
norfenfluramine (Schechter, 1989) substitute for MDMA, but not for LSD (Callahan
& Appel, 1988). The present findings also support the notion that the stimulus effects
of MDMA and d-amphetamine are clearly different (Goodwin & Baker, 2000;
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Nichols, 1986; Schechter, 1997). Moreover, it appears that even in animals trained to
discriminate a serotonin agonist (LSD) from MDMA, 5-HT release is a more salient
feature of MDMA’s discriminative stimulus effects than is dopamine release.
Because d-amphetamine produced partial substitution for MDMA, it is
possible that these effects could be potentiated by lower doses of fenfluramine.
Therefore, d-amphetamine and fenfluramine were tested in combination. Neither the
0.25 mg/kg nor the 0.50 mg/kg dose of fenfluramine resulted in any MDMAappropriate responding when given alone, while the 1.0 mg/kg dose of amphetamine
produced only 34.5% MDMA-appropriate responding when administered alone. It
was hypothesized that combining low doses of both compounds would result in a
synergistic effect and produce generalization to the MDMA stimulus. Only one
combination of d-amphetamine and fenfluramine completely substituted for MDMA
(0.50 mg/kg d-amphetamine and 0.50 mg/kg fenfluramine). Interestingly, when the
dose of d-amphetamine was increased to 1.0 mg/kg and combined with 0.50 mg/kg of
fenfluramine, the amount of MDMA-appropriate responding decreased from 80% to
65%. Additionally, 1.0 mg/kg d-amphetamine and 0.25 mg/kg fenfluramine
produced nearly complete substitution (79%) for the MDMA stimulus.
MDL-100907, a 5 -HT2 antagonist, has been reported to block both MDMA
stimulated dopamine release and long-term 5-HT deficits associated with MDMA
(Schmidt, 1992). However, in the present study, MDL-100907 had differential
effects when administered in combination with MDMA. No clear linear relationship
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was observed between MDL 100,907 dose and MDMA-appropriate responding.
Indeed, as is evident in the Figure 7, the percentage o f drug lever-responses at ail of
the MDL-100907 doses was highly variable among subjects. At one dose o f MDL100907 (0.0625 mg/kg) there was only 27% MDMA-appropriate responding, though
this was neither the highest nor the lowest dose tested. At a lower dose (0.03125
mg/kg) MDMA appropriate responding was 83%, while a dose of 0.125 mg/kg
produced 67% MDMA-appropriate responding. Moreover, at the highest dose of
MDL-100907 tested (0.50 mg/kg) there was 70% MDMA-appropriate responding.
This supports previous reports that multiple 5-HT receptor subtypes may be involved
in producing the stimulus effects of MDMA. Specifically, 5-HTi and 5 -HT2
antagonists (Glennon et al., 1992; Schechter, 1989) have been reported to decrease
MDMA-appropriate responding and 5 -HT3 antagonists have been reported to
completely block the MDMA cue(Glennon et al., 1992).
Conversely, MDL-100907 completely blocked the LSD cue at all of the doses
tested, including the dose which resulted in the lowest percentage of MDMAappropriate responding (0.0625 mg/kg). This supports previous reports that the
stimulus properties of LSD are mediated primarily through its actions on 5 -HT2
receptors (Bonson et al., 1996; Cameron & Appel, 1973; Glennon et al., 1982; Sadzot
et al., 1989; Trulson et al., 1976).
Haloperidol, a dopamine antagonist, failed to decrease MDMA-appropriate
responding at any of the doses tested. This further supports the notion that the
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stimulus effects of MDMA were not primarily mediated via its actions on dopamine
receptors in this procedure. However, this is contrary to a previous report that
haloperidol decreased the subjective, euphoric effects o f MDMA when given prior to
MDMA in fourteen healthy volunteers (Liechti & Vollenweider, 2000).
Three major conclusions have been gained from the present study. First, the
stimulus properties of MDMA consist of multiple actions, and are distinctly different
from the discriminative stimulus effects of both LSD and d-amphetamine. Thus, one
may argue it is not appropriate for MDMA to be classified into the traditional
hallucinogen and stimulant drug classes. Second, whether animals are trained to
discriminate MDMA from d-amphetamine or from LSD, serotonin release is a salient
feature of MDMA discrimination. However, the failure of MDL-100907 to fully
block MDMA discrimination in the present study suggests that other 5-HT receptor
mediated actions are also involved. A combination o f a serotonin and dopamine
antagonists may block the stimulus effects of MDMA in this procedure.
Unfortunately, due to the advanced age of the subjects further tests could not be
conducted. Thus, a third major conclusion is that although three-lever drug
discrimination procedures provide a more sensitive tool with which to investigate
drugs with compound stimulus properties, the time required to train such a
discrimination limits the number of compounds that can be assessed for stimulus
generalization and stimulus antagonism. Indeed, although the present study
established that the discriminative stimulus effects o f LSD and MDMA can be

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

58

differentiated, the amount of information obtained regarding pharmacological actions
mediating the stimulus properties of MDMA was limited by the extensive amount of
time required to establish and maintain stimulus control in this procedure.
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W I i S ii r n M i c h i g a n U n i v e r s i i y
March I S. 2000
B ru c e B c (c c k , I’ll I)
IA C U C C h a ir

Biological Sciences Department
W estern M ichigan University

Dear Dr. Bcjcek:

In regards to the IACUC committee’s concerns for protocol (00-02-02) entitled
“Application o f differential outcomes to a three-choice drug discrimination utilizing LSD
and MDMA”:
1) Animals will be exposed to training sessions six days per week. Drug will not be
administered for more than two consecutive training days. Test sessions will occur
once per week on average. That is, one training day for each condition (i.e., LSD,
MDMA, and saline) will separate test days. Thus, test sessions will occur
approximately once every four days. The total time duration for the study will be
approximately 52 weeks.
2) The principal investigator will monitor animals for one hour after testing for
complications. Additionally, a full time animal care staff monitors the health o f all
animals on a daily basis. If complications should arise where an animal is in obvious
pain and/or distress, C 0 2 will be used to euthanize the animal. Additionally, a
veterinarian is available for consultations.
3) The database search included the years 1960 through the present
Thank you for your time and consideration.
Sincere!^,

LlfSa Baker, Ph.tf.
Psychology Department
Western Michigan University
Kalamazoo, MI 49008

Amy Goddwjh, MA
Psychology Department
Western Michigan University
Kalamazoo, MI 49008
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